Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632695 | 0.92 | CYP3A4 (0.39) | CYP3A4LPAR3LPAR1LPAR2TDP1 | |
| SCHEMBL3716029 | 0.87 | CYP3A4 (0.34) | CYP3A4TSHRPPARDALDH1A1 | |
| SCHEMBL3817581 | 0.81 | CYP3A4 (0.67) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL379401 | 0.79 | CYP3A4 (0.55) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL27577557 | 0.78 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL23671685 | 0.77 | ALDH1A1 (0.50) | CYP3A4TSHRTDP1PPARDALDH1A1 | |
| SCHEMBL29310328 | 0.76 | TSHR (0.47) | CYP3A4TSHRALDH1A1 | |
| SCHEMBL30886725 | 0.76 | CA1 (0.35) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL3815405 | 0.76 | CYP3A4 (0.46) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL28012459 | 0.76 | CYP3A4 (0.46) | CYP3A4LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485085-A4 | PHOSPHATE PRODRUGS OF FLUOROOXINDOLES | BRISTOL MYERS SQUIBB CO (US) | 2007-03-14 | — | — | EP | disclosed |
| US-6930100-B2 | Phosphate prodrugs of fluoroxindoles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1485085-A1 | PHOSPHATE PRODRUGS OF FLUOROOXINDOLES | Bristol-Myers Squibb Company (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030195169-A1 | Phosphate prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | disclosed |
| WO-2003080047-A1 | PHOSPHATE PRODRUGS OF FLUOROOXINDOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195169-A1 | Phosphate prodrugs of fluorooxindoles | KCNA5, KCNN3, CACNA1E | CYP3A4 525/4885LPAR3 609/4885LPAR1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.